Results 51 to 60 of about 5,310,608 (313)

Can neurodegenerative disease be defined by four 'primary determinants':anatomy, cells, molecules, and morphology? [PDF]

, 2016
Traditional methods of describing and classifying neurodegenerative disease are based on the clinico-pathological concept supported by molecular pathological studies and defined by 'consensus criteria'.
Armstrong, Richard A., Richard A. Armstrong   +1 more
core   +1 more source

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

Molecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad, Silvio Carlo Ermanno Tosatto, Emanuela Leonardi   +2 more
wiley   +1 more source

Glycoproteomics in neurodegenerative diseases [PDF]

Mass Spectrometry Reviews, 2009
AbstractProtein glycosylation regulates protein function and cellular distribution. Additionally, aberrant protein glycosylations have been recognized to play major roles in human disorders, including neurodegenerative diseases. Glycoproteomics, a branch of proteomics that catalogs and quantifies glycoproteins, provides a powerful means to ...
Hwang, Hyejin, Zhang, Jianpeng, Chung, Kathryn A., Leverenz, James B., Zabetian, Cyrus P., Peskind, Elaine R., Jankovic, Joseph, Su, Zhen, Hancock, Aneeka M., Pan, Catherine, Montine, Thomas J., Pan, Sheng, Nutt, John, Albin, Roger L., Gearing, Marla, Beyer, Richard P., Shi, Min, Zhang, Jing   +17 more
openaire   +3 more sources

Sphingolipids in neurodegenerative diseases

Frontiers in Neuroscience, 2023
Neurodegenerative Diseases (NDDs) are a group of disorders that cause progressive deficits of neuronal function. Recent evidence argues that sphingolipid metabolism is affected in a surprisingly broad set of NDDs. These include some lysosomal storage diseases (LSDs), hereditary sensory and autonomous neuropathy (HSAN), hereditary spastic paraplegia ...
Xueyang Pan, Xueyang Pan, Debdeep Dutta, Debdeep Dutta, Shenzhao Lu, Shenzhao Lu, Hugo J. Bellen, Hugo J. Bellen, Hugo J. Bellen   +8 more
openaire   +4 more sources

Metabolite profiling of Alzheimer's disease cerebrospinal fluid [PDF]

, 2012
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive loss of cognitive functions. Today the diagnosis of AD relies on clinical evaluations and is only late in the disease.
Schmitz, Oliver, Czech, Christian, Senn Hans, Hampel Harald, Kristina Busch, Oliver Schmitz, Veronique Most (183225), Wiemer Jan, Wiemer, Jan, Jan Wiemer, Hans Senn, Jürgen Kastler, Peter Berndt, Harald Hampel, Schmitz Oliver, Jürgen Kastler (183232), Kastler, Jürgen, Christian Czech, Peter Berndt (183205), Busch, Kristina, Kristina Busch (183211), Jan Wiemer (183220), Veronique Most, Hans Senn (183234), Hampel, Harald, Oliver Schmitz (183214), Berndt, Peter, Berndt Peter, Most, Veronique, Harald Hampel (183230), Czech Christian, Most Veronique, Christian Czech (183197), Senn, Hans, Busch Kristina, Kastler Jürgen   +35 more
core   +2 more sources

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

Modification of Hospitalization Risk by Gender and Dementia Status Between the Ages of 85 and 95 in a German Cohort Based on Health Claims Data

BMC Health Services Research
Background Hospitalizations among older adults differ by dementia status, gender, and living arrangements. Understanding these differences, particularly in advanced age (age 85 and above), can inform appropriate healthcare strategies.
Gabriele Doblhammer, Elena Rakuša, Anne Fink   +2 more
doaj   +1 more source

Impaired Interoceptive Accuracy in Semantic Variant Primary Progressive Aphasia

Frontiers in Neurology, 2017
BackgroundInteroception (the perception of internal bodily sensations) is strongly linked to emotional experience and sensitivity to the emotions of others in healthy subjects.
Charles R. Marshall, Charles R. Marshall, Chris J. D. Hardy, Lucy L. Russell, Camilla N. Clark, Katrina M. Dick, Emilie V. Brotherhood, Rebecca L. Bond, Catherine J. Mummery, Jonathan M. Schott, Jonathan D. Rohrer, James M. Kilner, Jason D. Warren   +12 more
doaj   +1 more source

Human Huntington’s disease pluripotent stem cell-derived microglia develop normally but are abnormally hyper-reactive and release elevated levels of reactive oxygen species

Journal of Neuroinflammation, 2021
Background Neuroinflammation may contribute to the pathogenesis of Huntington’s disease, given evidence of activated microglia and elevated levels of inflammatory molecules in disease gene carriers, even those many years from symptom onset. We have shown
Grace C. O’Regan, Sahar H. Farag, Caroline S. Casey, Alison Wood-Kaczmar, Jennifer M. Pocock, Sarah J. Tabrizi, Ralph Andre   +6 more
doaj   +1 more source

Yeast Gcn2 retains activity following humanization of its auto‐phosphorylation region

FEBS Open Bio, EarlyView.
Using Saccharomyces cerevisiae as a model to study Gcn2 activation and regulation is limited by the lack of antibodies detecting phosphorylated Gcn2. To overcome this, we engineered Gcn2‐HsC, a yeast Gcn2 variant recognizable by commercial anti‐human phospho‐GCN2 antibodies.
Reuben A. Anderson, Anja H. Schiemann, Evelyn Sattlegger   +2 more
wiley   +1 more source